TriSalus Life Sciences Inc. (TLSI)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $149.93M
Last updated: Nov 17, 2026 at 11:05 AM ET
TriSalus Life Sciences Inc. (TLSI) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, TriSalus Life Sciences reported EPS of -$0.15, below the -$0.14 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TLSI's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
TLSI Earnings Call
The latest TLSI earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 12 quarters below that had an estimate, TLSI beat 4 and missed 8. Revenue for the quarter ended Sep 30, 2026 was $12.88M, up 11.3% from $11.57M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.15 | -$0.14 | -$0.15 - -$0.09 | -7.14% | Miss | N/A | 5 | 0 up, 0 down | Nov 10, 2026 | $12.88M |
| Jun 30, 2026 | -$0.16 | -$0.15 | -$0.19 - -$0.14 | -6.67% | Miss | N/A | 4 | 0 up, 1 down | Aug 6, 2026 | $11.41M |
| Mar 31, 2026 | $0.03 | -$0.16 | -$0.16 - -$0.16 | +118.38% | Beat | N/A | 1 | 0 up, 1 down | May 12, 2026 | $8.90M |
| Dec 31, 2025 | -$0.05 | -$0.13 | -$0.13 - -$0.13 | +61.54% | Beat | N/A | 1 | 0 up, 1 down | Mar 5, 2026 | $13.21M |
| Sep 30, 2025 | -$0.87 | -$0.16 | -$0.19 - -$0.14 | -443.75% | Miss | N/A | 2 | 1 up, 2 down | Nov 13, 2025 | $11.57M |
| Jun 30, 2025 | -$0.23 | -$0.22 | -$0.24 - -$0.19 | -4.55% | Miss | N/A | 3 | 1 up, 2 down | Aug 12, 2025 | $11.21M |
| Mar 31, 2025 | -$0.33 | -$0.20 | -$0.26 - -$0.09 | -65.00% | Miss | N/A | 3 | 1 up, 0 down | May 15, 2025 | $9.17M |
| Dec 31, 2024 | -$0.40 | -$0.35 | -$0.35 - -$0.35 | -14.29% | Miss | N/A | 1 | 0 up, 0 down | Mar 27, 2025 | $8.26M |
| Sep 30, 2024 | -$0.40 | -$0.36 | -$0.37 - -$0.36 | -11.11% | Miss | N/A | 2 | 0 up, 0 down | Nov 14, 2024 | $7.35M |
| Jun 30, 2024 | -$0.21 | -$0.46 | N/A | +54.35% | Beat | N/A | 3 | 0 up, 0 down | Aug 14, 2024 | $7.36M |
| Mar 31, 2024 | -$0.60 | -$0.72 | -$0.72 - -$0.58 | +16.67% | Beat | N/A | 2 | 0 up, 0 down | May 15, 2024 | $6.46M |
| Dec 31, 2023 | -$1.56 | -$0.69 | -$0.69 - -$0.69 | -126.09% | Miss | N/A | 1 | 0 up, 0 down | Mar 12, 2024 | $5.72M |
| Sep 30, 2023 | -$0.13 | N/A | N/A | N/A | N/A | -762.0% | N/A | N/A | Nov 14, 2023 | $5.19M |
| Jun 30, 2023 | -$0.12 | N/A | N/A | N/A | N/A | -254.1% | N/A | N/A | Aug 30, 2023 | $4.61M |
| Mar 31, 2023 | -$0.05 | N/A | N/A | N/A | N/A | -160.7% | N/A | N/A | Jun 29, 2023 | $2.98M |
| Dec 31, 2022 | -$0.01 | N/A | N/A | N/A | N/A | -111.1% | N/A | N/A | Mar 30, 2023 | $8.47M |
| Sep 30, 2022 | $0.02 | N/A | N/A | N/A | N/A | -66.7% | N/A | N/A | Nov 10, 2022 | $3.92M |
| Jun 30, 2022 | $0.08 | N/A | N/A | N/A | N/A | +700.0% | N/A | N/A | Aug 10, 2022 | N/A |
| Mar 31, 2022 | $0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 11, 2022 | N/A |
| Dec 31, 2021 | $0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 2, 2022 | $2.57M |
| Sep 30, 2021 | $0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 13, 2021 | N/A |
| Jun 30, 2021 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 16, 2021 | N/A |
| Mar 31, 2021 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 28, 2021 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.48, after -$1.61 the year before. It was $0.15 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.48 | N/A |
| Dec 31, 2024 | -$1.61 | N/A |
| Dec 31, 2023 | -$1.87 | -1139.1% |
| Dec 31, 2022 | $0.18 | N/A |
| Dec 31, 2021 | $0.15 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,800 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,809 | 9 | |
| 2026Q1 | Mar 31, 2026 | 4,803 | 8 | |
| 2025Q4 | Dec 31, 2025 | 5,218 | 8 | |
| 2025Q3 | Sep 30, 2025 | 5,221 | 10 | |
| 2025Q2 | Jun 30, 2025 | 4,929 | 7 | |
| 2025Q1 | Mar 31, 2025 | 5,701 | 11 | |
| 2024Q3 | Sep 30, 2024 | 6,255 | 8 | |
| 2024Q2 | Jun 30, 2024 | 4,224 | 8 |
2026Q3 Earnings Call
Opening remarks
Unknown Attendee Company Representative Good morning, and thank you for participating in today's call. Joining me from TriSalus are Mary Szela, President and Chief Executive Officer; David Patience, Chief Financial Officer; and Dr. Richard Marshall, Chief Medical Officer. Earlier today, TriSalus issued a press release announcing financial results for the quarter ended September 30, 2026. A copy of the press release is available on the Investor Relations section of the company's website. Before we begin, I'd like to remind you that management will make remarks during this call that include forward-looking statements within the meaning of federal securities laws and that these are being made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our Forms 10-Q and 10-K on file with the SEC and available on EDGAR, as well as our other periodic filings. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 10, 2026. TriSalus disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. And with that, I will turn the call over to Mary.
Mary Szela President and Chief Executive Officer Good morning, and thank you all for joining us. The third quarter marked an important period of growth and advancement for TriSalus. We drove increasing revenue, both year-over-year and quarter-over-quarter, as our commercial expansion continued and account utilization improved. In addition, in September, we received FDA clearance for TriNav Advance, enabling us to expand our portfolio looking forward. TriNav Advance extends our pressure-enabled drug delivery approach, called PEDD, to small distal vessels through the microcatheter of the physician's choice. These are vessels that TriNav technology could not previously fully address. With TriNav Advance, we now can address the full range of vessels encountered in liver embolization procedures. That means interventional radiologists can keep their preferred workflow while patients still benefit from PEDD. We are now preparing for a limited market release of TriNav Advance to gather early clinical and customer feedback before a broader launch. Milestones like this matter because of the problem we set out to solve. Catheter-based oncology drug delivery has changed very little in decades, even as therapies themselves have advanced dramatically.
Frequently Asked Questions About TLSI
Did TLSI beat earnings estimates last quarter?
No. TriSalus Life Sciences reported EPS of -$0.15 for the quarter ended Sep 30, 2026, below the -$0.14 estimate by 7.14%.
What EPS do analysts expect from TLSI next quarter?
The consensus EPS estimate for TriSalus Life Sciences for the quarter ending Dec 31, 2026 is -$0.06 from 7 analysts, with estimates from -$0.11 to -$0.04.
How often does TLSI beat earnings estimates?
TriSalus Life Sciences beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -45.18%.
TLSI pages: Overview, Earnings, Forecast, Financials, Competitors